3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Q3 FY2021 Earnings Presentation
36 slides from 3b Blackbio Dx's earnings presentation, Feb 5, 2021
Slide 1: Kilpest India Limited cover letter to BSE
KILPEST INDIA LIMITED REGD. OFFICE & FACTORY : 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 INDIA Morsooresece | Tel; 91-755 2686536, 2586537 FAX NO. : 91-755 2580438 E-mail : kilpest@bsnl.in Visit us at : www.kilpest.com kllpestbpl@yahoo.co.in CIN : L24211MP1972PLC001131 February 5, 2021 The
Slide 2: Investor Presentation Feb 2021
Farmer’s Trusted Agro-Input Partner for 48 Years Reliable and Affordable Healthcare Diagnostic Solutions INVESTOR PRESENTATION Feb’ 2021
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation t
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 • Health &
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of the art facility located in the center of India - with GST implementation this should give a boost to the company • 48 yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights 4269.44 KILPEST (Consolidated) Q3F21 Q3 FY20 2628.30 521.52% 1100.30% Net sales 4269.44 686.93 Profit before tax 2628.30 218.97 Q3F21 Profit after tax 1966.87 173.74 686.93 Q3F20 218.97 Paid up Equity share capital 750.81 750.81 Revenue PBT Reserves 1636.39 727
Slide 7: Present Market Overview/Outlook
Present Market Overview/Outlook • Sales during the first nine months remains static for agrochemicals due to COVID-19 Lockdown • Company will continue to focus on Public Health/warehousing sector and exports. As due to COVID-19, Private agriculture market is uncertain, and management doesn’t want to
Slide 8: From the house of Kilpest India Ltd.
Since 1972 From the house of Kilpest India Limited, KILPEST INDIA LTD. India’s most trusted agro-chemical brand proudly brings First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GEN
Slide 9: From the house of KILPEST India Ltd.
From the house of KILPEST India Ltd. 3B BlackBio Biotech India Limited has become India’s leading healthcare company specialized in the development of molecular biology fine-chemicals as tools for diagnostic/ pathology segment of healthcare. The Company is CDSCO Licensed, ISO 13485:2016 certified, G
Slide 10: TRUPCR from 3B BlackBio Biotech (I) Ltd.
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Vision Reliable and affordable healthcare solutions for all Mission 3B BlackBio Biotech (I) Ltd. with its TRUPCR® brand of products is committed to design and develop molecular diagnostics products of superior quality and value that continuously improves the
Slide 11: Timeline & Milestones
Timeline & Milestones COVID-19 YEAR GONE GLOBAL TRUPCR® Launching SARS-CoV- Oncopanels 2 Launch of Solid Tumor AML qPCR Extending Menu with ALL Kit Virology & EGFR Public MPN Adding (USFDA- Health KRAS Virology EUA) Entering & Launch of HBV, HCV NGS Panels Oncology & Expanding Geno, HIV Early Human
Slide 12: Growth Canvas
Growth Canvas ₹19,737.10 400 Apr. – Dec. 2020 ₹19,737.10 300 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 13: Financial Highlights Q3-FY21
Financial Highlights Q3-FY21 2572.85 3986.86 893.76% 1041.21% 401.19 225.45 Revenue EBITDA 2554.85 1072.22% 1907.55 1003.14% Q3FY21 Q3FY20 217.95 172.92 PBT PAT Rs. In Lakhs. ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 14: Events related to COVID-19
Events related to COVID -19 1. The company got approval from ICMR on 2nd April, 2020 and license from CDSCO on 4th April, 2020 for selling RT-PCR Kit for COVID-19, under its brand name TRUPCR® SARS-CoV-2 RT qPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 2.0, This test comes wit
Slide 15: Business Outlook, Exports, Utilization of Funds
Business Outlook Due to COVID-19, nationally and internationally, number of Molecular Diagnostics Labs have increased manifolds, but with COVID-19 infections potentially decreasing in 2021, lot of labs might shut down due to non-viability, still there would be substantially more labs than in 2019. A
Slide 16: Amalgamation, Dividend Payment, COVID-19 Scenario
Amalgamation The process has been started and application has also been filed with BSE, queries have been received and are being replied to. The process including NCLT order should be completed in FY22. Dividend Payment We will continue with payment of dividend policy as per previous years with incr
Slide 17: New Business Verticals
New Business Verticals The company’s vision is to focus on new verticals to continue on the path of business growth. R&D TRU TRURAPID® NGS® Although, NGS development TRURAPID® is based on the work had picked up pace during lateral flow technology in which Pre-Covid months, however, due we are develo
Slide 18: Our Beneficiaries
Our Beneficiaries FOR PATIENTS FOR LABORATORIES CLINICALLY VALIDATED PRECISE TRUPCR® kits are calibrated to WHO standards and clinically TRUPCR® offers highly sensitive and precise qPCR assays as validated on wide variety and numbers of samples. indicated by minimum variability of replicates and mul
Slide 19: Work Process
Work Process PLAN RESEARCH Feasibility DESIGN DEVELOP VALIDATIONS APPROVALS COMMERCIALIZATION (Technical & Commercial) IMPROVEMENT SUPPORT ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 20: R&D and People
R&D R&D People • Highly educated team of scientist from varied backgrounds • Dedicated teams for respective segments • Separate onco team headed by researchers (Ph.Ds.) from oncology background • Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases backgrou
Slide 21: Product QC - Our Strength
Product QC - Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 22: Our Certificates
Our Certificates US FDA EUA COVID-19 RT-PCR Kit CDSCO Licensed Diagnostic Kits ISO 13485:2016 Certified Company ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 23: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Sanger Sequencing Next Generation Mass Spec Sequencing Hybridization Microarray Low Volume ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 24: Molecular Diagnostics
Molecular Diagnostics • The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. • Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual’s genetic code and how their cells express the
Slide 25: Product Segments
Product Segments ONCOLOGY ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 26: All Inclusive TRUPCR Products
All Inclusive TRUPCR® Products TRUPCR range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis TRUPCR Nucleic Acid Extraction ki
Slide 27: Next Generation Sequencing
Next Generation Sequencing Launching soon… Next Generation Sequencing Assays Real image of NGS facility at 3B BlackBio Biotech (I) Ltd. Bhopal, India ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 28: Our National Presence
Our National Presence TRUPCR® range of products is currently used by: 400+ Users Across 80+ Cities ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 29: Going Global
Going Global TRUPCR® is now a global brand with its presence in: Europe South East Asia Middle East USA Africa ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 30: New Products Launched in FY 2020-21
New Products Launched in FY 2020-21 TRUPCR® PIK3CA Mutation Kit Qualitative Detection of PIK3CA Mutations on real-time PCR TRUPCR® IDH1/2 Detection Kit Detection of IDH1 and IDH2 mutations using real-time PCR TRUPCR® SARS-CoV-2 RT qPCR Kit (Version 2.0) & (Version 3.2) Detection of SARS-CoV-2 virus
Slide 31: Global Recognition
Global Recognition ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 32: Contractual Business and Tender Business
Contractual Business • We are happy to inform that the Company to ensure long term assured business, has started signing long term (2-3 yr) contract with large customers. • As on date the company has seven contracts running which ensure yearly business of up to Rs. 70 - 80 Million total from these s
Slide 33: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs • Evolution of disease profiles. New viruses and cancers are been diagnosed External Growth Drivers • Increase in evidence-based treatments /
Slide 34: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 35: Outstanding Achievement Award for Excellence in R&D by FMPCCI
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‘Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category’, during the 4th Outstanding Achievement Award 2016, held o
Slide 36: JAI HIND
JAI HIND ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS